B cell depletion therapy does not resolve chronic active multiple sclerosis lesions.

ABSTRACT:

Background

Chronic active lesions (CAL) in multiple sclerosis (MS) have been observed even in patients taking high-efficacy disease-modifying therapy, including B-cell depletion. Given that CAL are a major determinant of clinical progression, including progression independent of relapse activity (PIRA), understanding the predicted activity and real-world effects of targeting specific lymphocyte populations is critical for designing next-generation treatments to mitigate chronic inflammation in MS.

Methods

We analyzed published lymphocyte single-cell transcriptomes from MS lesions and bioinformatically predicted the effects of depleting lymphocyte subpopulations (including CD20 B-cells) from CAL via gene-regulatory-network machine-learning analysis. Motivated by the results,

SUBMITTER: Maggi P 

PROVIDER: S-EPMC10436266 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature